852673-26-8

Basic information

• Product Name: 2-[2-(4-aminophenyl)ethylamino]-4-(2-hydroxyethylamino)-6-phenylamino-1,3,5-triazine
• Synonyms: 2-[2-(4-aminophenyl)ethylamino]-4-(2-hydroxyethylamino)-6-phenylamino-1,3,5-triazine
• CAS NO: 852673-26-8
• Molecular Weight: 365.438
• Mol File: 852673-26-8.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 2-[2-(4-aminophenyl)ethylamino]-4-(2-hydroxyethylamino)-6-phenylamino-1,3,5-triazine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-[2-(4-aminophenyl)ethylamino]-4-(2-hydroxyethylamino)-6-phenylamino-1,3,5-triazine(852673-26-8)
• EPA Substance Registry System: 2-[2-(4-aminophenyl)ethylamino]-4-(2-hydroxyethylamino)-6-phenylamino-1,3,5-triazine(852673-26-8)

Safety Data

• Hazardous Substances Data: 852673-26-8(Hazardous Substances Data)

Upstream product

• 13472-00-9 p-Aminophenethylamine 
• 24799-62-0 2-(4-anilino-6-chloro-[1,3,5]triazin-2-ylamino)-ethanol 

Downstream Products

• 852673-27-9 2-{4-[2-(4-{4-chloro-6-phenylamino-[1,3,5]triazin-2-ylamino}-phenyl)-ethylamino]-6-phenylamino-[1,3,5]triazin-2-ylamino}-ethanol 

Relevant articles and documents

TRIAZINE DIMERS FOR THE TREATMENT OF AUTOIMMUNE DISEASES

Compounds containing two mono- or disubstituted triazine rings covalently linked by an organic linker, but not linked directly to each other, may be used to treat autoimmune diseases. Autoimmune diseases which are amenable to treatment with compounds of this invention include rheumatoid arthritis, systemic lupus erythematosus (SLE), idiopathic (immune) thrombocytopenia (ITP), glomerulonephritis and vasculitis. The present invention also relates to reducing drug toxicity which often accompanies traditional therapies for autoimmune diseases. The compounds may also be used to bind antibody in vitro or ex vivo.